#USA #San Diego #Robbins LLP #Pacira BioSciences #PCRX

Pacira BioSciences Inc. Faces Class Action Due to Alleged Patent Misrepresentation

Robbins LLP has recently highlighted a significant class action lawsuit aimed at Pacira BioSciences, Inc. (NASDAQ: PCRX). The case concerns investors who purchased stock during a specific period, from August 2, 2023, to August 8, 2024, when the pharmaceutical company was allegedly misrepresenting the patent protections of its flagship product, Exparel.

Background of the Case

Pacira BioSciences, recognized for its focus on non-opioid pain management solutions, claimed that the patent protections surrounding its product Exparel were robust. This information was crucial for the company’s projected growth and investor confidence. However, the reality was starkly different, as revealed in the recent legal developments.

The class action lawsuit suggests that Pacira misled shareholders about the validity of the ‘495 patent which supported Exparel. A court ruling on June 6, 2023, indicated that the patent was not as enforceable as Pacira had led investors to believe. This crucial misinformation has raised serious concerns regarding the integrity of the company's public communication and its responsibilities to its investors.

As news of the patent issues broke, it became evident that Exparel, responsible for nearly 80% of Pacira's revenue, lacked the necessary protections to prevent competition from generic manufacturers. This revelation culminated in a dramatic stock price drop from $22.36 per share on August 8, 2024, to $11.70 the following day, representing a staggering loss of over 47% in just one day.

What This Means for Shareholders

For shareholders who suffered significant losses due to these developments, there is an opportunity to get involved in the class-action lawsuit. Robbins LLP is urging those impacted by the plummeting stock prices to get in touch with the firm directly for guidance on their rights and options.

Investors interested in taking a leadership role in the litigation process should file their applications to act as lead plaintiffs by March 14, 2025. While participation as a lead plaintiff offers a more active role in the lawsuit, it is not a requirement for recovering losses, as shareholders can also opt to remain absent class members while still benefitting from any legal settlement.

About Robbins LLP

Robbins LLP is notable in the field of shareholder rights litigation. With over two decades of experience, the firm aims to provide representation to investors who want to recover losses and demand accountability from corporate leaders for any wrongdoing. The firm operates on a contingency fee basis, meaning shareholders incur no upfront costs. All fees and expenses are only charged if the case is won.

Conclusion

The upcoming developments in the Pacira class action case are essential for shareholders who have been affected by the alleged patent misrepresentation. As legal proceedings begin to unfold, it is vital for investors to stay informed and proactive about their rights. Whether through participation in the class action or by staying connected with updates from Robbins LLP, shareholders should take steps to ensure their financial interests are protected during this tumultuous period for the company.

For more information on how to engage with this process or to receive updates about ongoing legal proceedings, investors can reach out to Robbins LLP through the recommended contact options.

• ---

This article provides insights into the current legal issues facing Pacira BioSciences and underscores the importance of corporate transparency and accountability in protecting investor interests.